Vanessa F. Bonazzi

Employment

• The University of Queensland Research Fellow
  2018 - 2023
• Queensland University of Technology Post doctoral Researcher
  2015 - Present
• Centre Mediterraneen de Medecine Moleculaire
  2013 - 2015
• Queensland Institute of Medical Research Research Officer
  2006 - 2013

Education

• Institut Curie PhD
  2002 - 2005
• Magistere de Genetique - Paris VII

Projects & Funding

Projects & funding information is unavailable.

Publications (40)

• C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients
  Vanessa Bonazzi, Lauren G. Aoude, Sandra Brosda +13 more
  Asia-Pacific Journal of Clinical Oncology 2025 DOI: 10.1111/ajco.13993
  +Save
• Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition
  npj Precision Oncology 2023 DOI: 10.1038/s41698-023-00478-6
  +Save
• Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
  Marjan Mojtabavi Naeini, Felicity Newell, Lauren G. Aoude +37 more
  Nature Communications 2023 DOI: 10.1038/s41467-023-38891-x
  +Save
• Data from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.c.6545076.v1
  +Save
• Data from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.c.6545076
  +Save
• Supplementary Figure 1 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526397
  +Save
• Supplementary Figure 1 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526397.v1
  +Save
• Supplementary Figure 2 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526394
  +Save
• Supplementary Figure 2 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526394.v1
  +Save
• Supplementary Figure 3 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526391
  +Save
• Supplementary Figure 3 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526391.v1
  +Save
• Supplementary Tables 1-4 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526388
  +Save
• Supplementary Tables 1-4 from Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  2023 DOI: 10.1158/1541-7786.22526388.v1
  +Save
• Radiomics biomarkers are associated with survival in patients with Oesophageal Adenocarcinoma
  2023 DOI: 10.21203/rs.3.rs-2684818/v1
  +Save
• Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.
  2023 DOI: 10.21203/rs.3.rs-2512859/v1
  +Save
• Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer
  Vanessa Bonazzi, Olga Kondrashova, Deborah S. Smith +20 more
  Genome Medicine 2022 DOI: 10.1186/s13073-021-00990-z
  +Save
• ctDNA as A Biomarker of Progression in Oesophageal Adenocarcinoma
  2021 DOI: 10.21203/rs.3.rs-1041840/v1
  +Save
• Characterizing the Heterogeneity of Small Extracellular Vesicle Populations in Multiple Cancer Types via an Ultrasensitive Chip
  Jing Wang, Alain Wuethrich, Richard J. Lobb +13 more
  ACS Sensors 2021 DOI: 10.1021/acssensors.1c00358
  +Save
• Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
  Lauren G. Aoude, Bernadette Z.Y. Wong, Vanessa Bonazzi +18 more
  Molecular Cancer Research 2021 DOI: 10.1158/1541-7786.MCR-20-1038
  +Save
• Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
  Lauren G. Aoude, Vanessa Bonazzi, Sandra Brosda +12 more
  Scientific Reports 2020 DOI: 10.1038/s41598-020-74956-3
  +Save